Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study [PDF]
VirusesBackground: The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy.
Jae Hyun Yoon +8 more
doaj +2 more sources
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort [PDF]
Scientific ReportsSimplified (“minimal monitoring”) pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and ...
Goki Suda +25 more
doaj +2 more sources
Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient [PDF]
Kidney MedicineCurrent direct-acting antiviral (DAA) regimens have achieved nearly universal viral eradication in hepatitis C virus (HCV) nucleic acid test (NAT)-positive donor to HCV-negative recipient (HCV NAT+/–) transplantation.
Shengliang He +8 more
doaj +2 more sources
Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis [PDF]
Frontiers in GastroenterologyIntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (
Liwei Zhuang +6 more
doaj +2 more sources
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo +24 more
doaj +1 more source
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis [PDF]
Clinical and Molecular Hepatology, 2021 Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis.
Po-Yao Hsu +23 more
doaj +1 more source
SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
Pakistan Armed Forces Medical Journal, 2021 Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study.
Arif Qayyum Khan +5 more
doaj +1 more source
Журнал инфектологии, 2023 Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.Materials and methods.
A. F. Novikova +3 more
doaj +1 more source
Journal of Education, Health and Sport, 2023 Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram +9 more
doaj +1 more source
Pharmaceutics, 2020 The limited aqueous solubility of many active pharmaceutical ingredients (APIs) is responsible for their poor performance and low drug levels in blood and at target sites. Various approaches have been adopted to tackle this issue.
Yasir Mehmood +12 more
doaj +1 more source